In brief
A Nature Medicine study forecasts a 20.2 % rise in cervical cancer cases and a 39.3 % rise in deaths by 2050, despite the disease’s preventability. Sub‑Saharan Africa will experience the largest surge, with cases nearly doubling and deaths almost doubling. The study urges expanded HPV vaccination, screening and treatment.
A modelling study published in Nature Medicine has warned that global cervical cancer cases will rise 20.2 % and deaths 39.3 % by 2050, with sub‑Saharan Africa taking the hardest hit, Xinhua reported from Sydney on Nov 3, 2026.
In 2023, the world recorded an estimated 887,000 new cervical cancer cases and 369,000 related deaths. The model projects that annual cases could reach 1.08 million and deaths 522,000 by 2050, a jump of 20.2 % and 39.3 % from 2024 levels, respectively.
Sub‑Saharan Africa is expected to see the biggest increase, with cases projected to rise by 88.7 % and deaths by 95.4 % to an estimated 206,000 deaths in 2050. The same region’s age‑standardized incidence rate is more than four times higher than that of high‑income countries, while its mortality rate is more than seven times higher, the study notes.
None of the seven global regions studied is forecast to meet the World Health Organization’s cervical cancer elimination threshold of fewer than four cases per 100,000 women by 2050.
None of the seven global regions assessed is forecast to meet the World Health Organization's cervical cancer elimination threshold of fewer than four cases per 100,000 women by 2050 if current trends continue.
This finding was reported by Xinhua.
Authors of the study urge broader access to HPV vaccination, screening and treatment, noting that availability of these interventions varies widely across the globe. As a largely preventable disease, the predicted rise underscores the need for intensified public‑health measures.
